Search
LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalLJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.
Categories: Compounds used in a research, industrial, or household settingCOVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection
go.drugbank.com/drugs/DB15845ExperimentalAs of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’ … The vaccine utilizes granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine known to enhance vaccine efficacy through prolongation of humoral and cell immunity.
Synonyms: AP-TP-V, COVID-19 AP TP VaccineAP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. … It is being pursued by Access Pharmaceuticals, Inc.
Betaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Categories: Antihypertensive Agents Indicated for HypertensionBuformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
V1003
go.drugbank.com/drugs/DB05046ExperimentalV1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalThis follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System
Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Hesperetin
go.drugbank.com/drugs/DB01094InvestigationalHesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.